WO2006038479A1 - アリールアシルアミダーゼ遺伝子、およびその利用方法 - Google Patents
アリールアシルアミダーゼ遺伝子、およびその利用方法 Download PDFInfo
- Publication number
- WO2006038479A1 WO2006038479A1 PCT/JP2005/017575 JP2005017575W WO2006038479A1 WO 2006038479 A1 WO2006038479 A1 WO 2006038479A1 JP 2005017575 W JP2005017575 W JP 2005017575W WO 2006038479 A1 WO2006038479 A1 WO 2006038479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- seq
- allylacylamidase
- vector
- transformant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
Definitions
- the present invention relates to a DNA encoding allylacylamidase and a method for producing allylacylamidase using the DNA.
- Alylacylamidase is defined by the International union of biochemistry (Enzyme Nomenclature, 1978, Academy Press, New York), It has been shown to have catalytic activity to hydrolyze lido to aline and fatty acid anions.
- Alylacyl amidase is an industrially useful enzyme that can be used for quantification of aryls such as acetaminophen (Patent Document 1).
- Aryl acylamidase is known to exist in mammals, higher plants, and microorganisms.
- mammals and higher plant-derived enzymes 1) it is difficult to obtain animals and plants that are the source of the enzyme, 2) the isolation procedure from animals and plants is complicated, and 3) microorganisms using genetic recombination technology. It is generally unsuitable for industrial production due to the difficulty of production by the host.
- microorganism-derived enzymes are often advantageous for industrial production with few such problems.
- Alylacylamidases isolated from microorganisms include those derived from Candida utilis (Non-patent document 1) and those derived from Bacillus sphaeri cus (non-patent document). 2), derived from Pseudomonas acido vorans (Non-patent document 3), derived from Pseudomonas fluorescens (Non-patent document 4), Rhodococcus ellis mouth police (Rhodococcus e rythropolis) (Patent Document 2), Coryneform 'Batterium' (Non-Patent Document 5), Pseudomonas sp. (Non-Patent Document 6), and Nocardia 'Nocardia globerula' (Patent Document 3, Non-Patent Document 7) has been reported.
- Non-Patent Document 1 J. Gen. Microbiol, 59, 47-55 (1969)
- Non-Patent Document 2 Appl. Microbiol, 26, 709-718 (1973)
- Non-Patent Document 3 Eur. J. Biochem., 53, 357-369 (1975)
- Non-Patent Document 4 Eur. J. Biochem., 132, 651-655 (1983)
- Non-Patent Document 5 Journal of Pesticide Science, 18, 211-216 (1993)
- Non-Patent Document 6 Sanop Misaengmul Hakhoechi, 26, 413-419 (1998)
- Non-Patent Document 7 Eur. J. Biochem., 199, 17-24 (1991)
- Patent Document 1 US Patent No. 4999288
- Patent Document 2 JP-A 63-74484
- Patent Document 3 JP-A-3-277281
- any of the allylacylamidases disclosed in the above documents can be isolated from the culture fluid of the microorganism from which they are derived. However, it is difficult to say that the methods for producing these allylacylamidases have low productivity per culture volume. In addition, there is no disclosure of information on the DNA encoding these allylacylamidases, and therefore it is not possible to improve the productivity of these allylacylamidases using genetic recombination technology. . Under such circumstances, there is a need for a more efficient method for producing arylacylamidase.
- An object of the present invention is to provide a method for producing allylacylamidase that is isolated from a DNA encoding allylacylamidase and uses the DNA. Means for solving the problem
- the inventors of the present invention have isolated DNA encoding allylicacyl amidase from a microorganism having allylacylamidase activity, and have clarified its base sequence.
- the DN Using A a transformant producing allylacylamidase was bred, and an efficient method for producing allylacylamidase using the transformant was established.
- one feature of the present invention is a DNA encoding allylacylamidase isolated from a microorganism having allylacylamidase activity. Another feature of the present invention is a polypeptide encoded by the DNA and having allylacylamidase activity. Another feature of the present invention is a vector containing the DNA. Another feature of the present invention is a transformant containing the vector. Furthermore, another feature of the present invention is a method for producing allylacylamidase using the transformant.
- the DNA of the present invention is a DNA that encodes allylamylamidase, and can be any untranslated region as long as it can express allylamylamidase in a host cell introduced according to the method described below. May be included.
- Such DNA can be isolated from microorganisms having allylacylamidase activity.
- the microorganism that is the origin of the DNA of the present invention is not particularly limited.
- the DNA can be isolated from Nocardia globerula NBRC 13510 strain.
- the microorganisms can be obtained from the Biological Resource Department of the Biotechnology Headquarters, National Institute of Technology and Evaluation (NBRC: 2-5-8 Kazusa Kazusa, Kisarazu, Chiba Prefecture, 292-0818).
- the DNA of the present invention can be obtained, for example, by the method shown below, Power can be isolated.
- the microorganism that is the source of the DNA of the present invention is cultured using an appropriate medium.
- a medium for culturing the microorganism a normal liquid nutrient medium containing a carbon source, a nitrogen source, inorganic salts, organic nutrients and the like can be used as long as the microorganism grows.
- allylacylamidase is isolated from the microorganism by appropriately combining commonly known protein purification methods. For example, the cells are collected from the culture solution of the microorganism by centrifugation or filtration, and the obtained cells are crushed by a physical method using an ultrasonic crusher or glass beads, and then centrifuged. The cell-free extract is prepared by removing the bacterial cell residue and using it for fractional precipitation, ion exchange chromatography, hydrophobic chromatography, Genore filtration chromatography, reverse phase chromatography, ultrafiltration, etc. Can isolate allylacylamidase.
- the activity of allylacylamidase is, for example, obtained by adding 10 ⁇ l of test solution to 990 1 in lOOmM glycine buffer (pH 9.5) containing 10 mM 2-methylaceto-lide (reaction substrate).
- a part of the amino acid sequence of the isolated allylacylamidase is determined. For example, after isolating the isolated allylacylamidase using an appropriate endopeptidase, the resulting peptide fragment is fractionated by reverse-phase HPLC, and this is separated into ABI492 protein sequencer (Applied Biosystems). A part of the amino acid sequence of aryl sylamidase can be determined.
- a part of DNA encoding allylacylamidase is amplified by PCR (Polymerase Chain Reaction), and its base sequence is determined.
- This step can be performed, for example, as follows. First, based on the amino acid sequence information obtained above, a PCR primer is synthesized to amplify a portion of the DNA encoding allylasilamidase. The Next, chromosomal DNA of the microorganism that is the source of the DNA is prepared by a conventional DNA isolation method, for example, the method of Visser et al. (Appl. Microbiol. Biotechnol., 53, 415 (2000)).
- PCR is carried out using the PCR primers described above to amplify a part of the DNA encoding allylamylamidase. Further, the base sequence of the amplified DNA is determined using ABI373A DNA Sequencer (Applied Biosystems) or the like.
- Examples of the DNA of the present invention thus obtained include DNA containing the base sequence shown in SEQ ID NO: 1 in the sequence listing.
- a DNA having a base sequence ability complementary to the base sequence shown in SEQ ID NO: 1 in the sequence listing and a DNA that is hybridized under stringent conditions and has allylacylamidase activity are also encompassed by the DNA of the present invention.
- a DNA consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 1 in the sequence listing and a DNA that hybridizes under stringent conditions are expressed as follows.
- a hybridization method or Southern hybridization method is performed, a hybrid that specifically has a DNA sequence having a complementary base sequence to the base sequence shown in SEQ ID NO: 1 in the sequence listing is formed.
- DNA is expressed as follows.
- stringent conditions include, for example, 75 mM trisodium citrate, 750 mM sodium chloride, 0.5% sodium dodecyl sulfate, 0.1% ushi serum albumin, 0.1% polypyrrolidone. And after hybridization at 65 ° C. in an aqueous solution composed of 0.1% Ficoll 400 (Amersham Biosciences), 15 mM trisodium citrate, 150 mM sodium chloride, And the conditions under which cleaning is performed at 60 ° C. using an aqueous solution that also has a composition of 0.1% sodium dodecyl sulfate.
- an aqueous solution having a compositional power of 15 mM trisodium citrate, 150 mM sodium chloride, and 0.1% sodium dodecyl sulfate is used. And more preferably under the above conditions.
- the washing is performed at 65 ° C. using an aqueous solution having a composition of 1.5 mM trisodium citrate, 15 mM sodium chloride, and 0.1% sodium dodecyl sulfate.
- the polypeptide of the present invention is a polypeptide that is encoded by the above-described DNA of the present invention and has aryl sylamidase activity.
- a polypeptide having the amino acid sequence ability shown in SEQ ID NO: 2 in the sequence listing encoded by the base sequence shown in SEQ ID NO: 1 in the sequence listing can be given.
- the polypeptide of the present invention is not limited to this, and is encoded by DNA consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 1 in the sequence listing and DNA that hybridizes under stringent conditions. Polypeptides having allylacylamidase activity are encompassed by the present invention.
- such a polypeptide can be prepared by using, as an appropriate vector, DNA that hybridizes under stringent conditions with DNA complementary to the base sequence shown in SEQ ID NO: 1 in the sequence listing. After ligation, it can be obtained by introducing into a suitable host cell and expressing.
- an amino acid is added to a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing. Can also be obtained by causing substitutions, insertions, deletions or additions.
- the number of amino acids to be substituted, inserted, deleted or added in the polypeptide is not limited as long as the arylacylamidase activity is not lost.For example, it is 20 amino acids or less, preferably 5 or less, more preferably Two or one.
- the vector of the present invention is a vector containing the DNA of the present invention.
- the vector used for introducing the DNA of the present invention into the host microorganism and expressing it in the introduced host microorganism can express the gene encoded by the DNA in an appropriate host microorganism. If it is, it will not be specifically limited. Examples of such vectors include plasmid vectors, fuzzy vectors, cosmid vectors, and shuttle vectors that can exchange genes with other host strains can also be used. Such vectors are usually lacU An expression vector containing control elements such as V5 promoter, trp promoter, trc promoter, tac promoter, lpp promoter, tufB promoter, recA promoter, pL promoter, etc. and operably linked to the DNA of the present invention It can be used suitably. For example, pUCNT (International Publication No. WO94Z03613) can be suitably used.
- regulatory element refers to a nucleotide sequence having a functional promoter and any related transcription element (eg, enhancer, CCAAT box, TATA box, SPI site, etc.).
- operably linked is a gene that is operably linked to various regulatory elements such as a promoter that regulates the expression of a gene, such as an enzyme. That means. It is a matter well known to those skilled in the art that the type and kind of the control factor can vary depending on the host.
- Examples of the vector of the present invention include pNTNG described later.
- pNTNG can be obtained by inserting the DNA shown in SEQ ID NO: 1 into the above-described expression vector pUCNT.
- the transformant of the present invention can be obtained by introducing the vector of the present invention into a host cell.
- the host cell into which the vector of the present invention is introduced is particularly preferably Escherichia coli, which includes bacteria, yeasts, filamentous fungi, plant cells, animal cells and the like.
- the vector of the present invention can be introduced into a host cell by a known method.
- Escherichia coli as the host cell, for example, the vector can be introduced into the host cell by using a commercially available E. coli HB101 competent cell (manufactured by Takara Bio Inc.).
- Examples of the transformant of the present invention include E. coli HB101 (pNTNG) FERM B P-10416, which will be described later.
- This transformant has the same accession number as of September 15, 2005, the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center ( ⁇ 305-8566 No. 6) deposited (transferred domestic deposited stock on 23rd October 2003 to international deposit based on the Budapest Treaty).
- allylacylamidase By culturing the transformant of the present invention, allylacylamidase is efficiently produced. Can be built.
- the culture of the transformant of the present invention can be carried out using a normal liquid nutrient medium containing a carbon source, a nitrogen source, inorganic salts, organic nutrients and the like as long as it grows.
- various inducers can be added to the medium to increase the amount of allylacylamidase produced per culture volume.
- Alylacylamidase accumulated in the culture medium of the transformant of the present invention can also be used as the arylylacylamidase-containing product in the culture medium, using a generally known protein purification method, It can also be used after purification or partial purification.
- This DNA fragment is cloned into the plasmid pT7Blue T—Vector (Novagen), ABI PRISM Dye Ter mmator and ycle 3 ⁇ 4eauencmg Readv Reaction Kit (Perkm Elmer: ⁇ )
- the base sequence was determined using ABI 373A DNA Sequencer (Perkin Elmer). The base sequence is shown in SEQ ID NO: 5 in the sequence listing.
- Nocardia globulara NBRC13510 strain chromosomal DNA is completely digested with restriction enzymes ApaLI, EcoRI, or Sphl, and the resulting digests are each intramolecular using T4DNA ligase (Takara Noo) Cyclized.
- T4DNA ligase Takara Noo Cyclized.
- iPCR method Nucl. Acids Res., 16, 8186 (1988)
- i-PCR was performed using TaKaRa EX Taq (manufactured by Takara Bio Inc.) as a DNA polymerase, and the reaction conditions were in accordance with the instruction manual.
- the base sequence was determined in the same manner as described above. The determined base sequence is shown in SEQ ID NO: 1 in the sequence listing. The amino acid sequence encoded by the base sequence is shown in SEQ ID NO: 2 in the sequence listing.
- primer 3 5 -gtgcatatggatgtcgccgaatacgc-3 '(SEQ ID NO: 6 in the sequence listing) and primer 4: 5-gacggatccttactaccggcccacgtgcacgg-3 (self sequence number 7 in the self sequence table)
- PCR was performed using the chromosomal DNA of Caldia globularula NBRC13510 strain as a saddle type.
- double-stranded DNA was obtained in which an Ndel recognition site was added to the start codon portion of the DNA consisting of the base sequence shown in SEQ ID NO: 1 in the sequence listing, and a BamHI recognition site was added immediately after the termination codon.
- PCR uses TaKaRa as a DNA polymerase
- LA Taq (manufactured by Takara Bio Inc.) was used, and the reaction conditions were in accordance with the instruction manual.
- This DNA was digested with Ndel and BamHI and inserted between the Ndel recognition site and the BamHI recognition site downstream of the lac promoter of plasmid pUCNT (International Publication No. WO 94Z03613) to construct a thread-replacement vector pNTNG.
- E. coli HB101 competent cells (Takara Bio Inc.) were transformed to obtain E. coli HBlOl (pNTNG).
- This transformant is independent as of September 15, 2005, with accession number FERM BP—10416. Deposited at the National Institute of Advanced Industrial Science and Technology Patent Biological Depositary Center (original deposit date)
- the transformant E. coli HBlOl (pNTNG) obtained in Example 3 was mixed with 2 XYT medium (200% / ml ampicillin, tryptone 1.6%, yeast extract 1.0%, NaClO. 5%, pH7. 0) and cultured at 37 ° C for 24 hours.
- the microbial cells were collected by centrifugation for lml of this culture, and suspended in lml of lOOmM phosphate buffer (pH 6.5). This was crushed using a UH-50 type ultrasonic homogenizer (manufactured by SMT), and then the cell residue was removed by centrifugation to prepare a cell-free extract.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006539226A JPWO2006038479A1 (ja) | 2004-10-04 | 2005-09-26 | アリールアシルアミダーゼ遺伝子、およびその利用方法 |
EP05785206A EP1811022A4 (en) | 2004-10-04 | 2005-09-26 | ARYLACYLAMIDASE GENE AND METHOD OF USE IDOINE |
US11/576,560 US20110236955A1 (en) | 2004-10-04 | 2005-09-26 | Arylacylamidase gene and method of using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-291916 | 2004-10-04 | ||
JP2004291916 | 2004-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038479A1 true WO2006038479A1 (ja) | 2006-04-13 |
Family
ID=36142557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017575 WO2006038479A1 (ja) | 2004-10-04 | 2005-09-26 | アリールアシルアミダーゼ遺伝子、およびその利用方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110236955A1 (ja) |
EP (1) | EP1811022A4 (ja) |
JP (1) | JPWO2006038479A1 (ja) |
WO (1) | WO2006038479A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002325587A (ja) * | 2001-03-02 | 2002-11-12 | Daicel Chem Ind Ltd | ニトリルヒドラターゼ、およびアミドの製造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4999288A (en) * | 1987-10-28 | 1991-03-12 | Gds Technology, Inc. | Test composition and method for the determination of anilides |
-
2005
- 2005-09-26 WO PCT/JP2005/017575 patent/WO2006038479A1/ja active Application Filing
- 2005-09-26 EP EP05785206A patent/EP1811022A4/en not_active Withdrawn
- 2005-09-26 US US11/576,560 patent/US20110236955A1/en not_active Abandoned
- 2005-09-26 JP JP2006539226A patent/JPWO2006038479A1/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002325587A (ja) * | 2001-03-02 | 2002-11-12 | Daicel Chem Ind Ltd | ニトリルヒドラターゼ、およびアミドの製造方法 |
Non-Patent Citations (4)
Title |
---|
See also references of EP1811022A4 * |
VAUGHAN PA ET AL: "Aryl acylamidase from Rhodococcus erythropolis NCIB 12273.", APPL MICROBIOL BIOTECHNOL., vol. 34, no. 1, 1990, pages 42 - 46, XP002993748 * |
VISSER H ET AL: "Cloning and characterization of an epoxide hydrolase-encoding gene from Rhodotorula glutinis.", APPL MICROBIOL BIOTECHNOL., vol. 53, no. 4, 2000, pages 415 - 419, XP002348540 * |
YOSHIOKA H ET AL: "Purification and characterization of aryl acylamidase from Nocardia globerula.", EUR J BIOCHEM., vol. 199, no. 1, 1991, pages 17 - 24, XP002993747 * |
Also Published As
Publication number | Publication date |
---|---|
US20110236955A1 (en) | 2011-09-29 |
EP1811022A4 (en) | 2007-11-21 |
EP1811022A1 (en) | 2007-07-25 |
JPWO2006038479A1 (ja) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4746548B2 (ja) | 新規カルボニル還元酵素、その遺伝子、およびその利用法 | |
US7553652B2 (en) | Process for the preparation of (S)- or (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid | |
AU3801899A (en) | Method for secretory production of human growth hormone | |
JP6044675B2 (ja) | D−サクシニラーゼ、およびこれを用いたd−アミノ酸の製造方法 | |
WO2007114217A1 (ja) | エリスロ又はスレオ-2-アミノ-3-ヒドロキシプロピオン酸エステルの製造方法、新規カルボニル還元酵素、その遺伝子、ベクター、形質転換体、およびそれらを利用した光学活性アルコールの製造方法 | |
KR20120099257A (ko) | 전 세포 바이오촉매 | |
JP5297656B2 (ja) | 新規枯草菌変異株及びタンパク質の製造方法 | |
JP4216719B2 (ja) | ハロゲン化合物耐性新規ギ酸脱水素酵素及びその製造方法 | |
WO2006038479A1 (ja) | アリールアシルアミダーゼ遺伝子、およびその利用方法 | |
JP4118687B2 (ja) | Arthrobacter crystallopoietes(アリスロバクテリア クリスタロポイテス)DSM20117株由来のD−カルバモイラーゼ | |
US6316242B1 (en) | Method for producing nitrile hydratase | |
JP4287144B2 (ja) | 新規ギ酸脱水素酵素及びその製造方法 | |
WO2015019674A1 (ja) | ムコール属由来のフラビンアデニンジヌクレオチド結合型グルコースデヒドロゲナーゼの生産方法 | |
WO2007099994A1 (ja) | 新規カルボニル還元酵素、その遺伝子、ベクター、形質転換体、およびそれらを利用した光学活性アルコールの製造方法 | |
JP4758580B2 (ja) | ニトリラーゼの選択性を調整する方法、前記方法によって得られるニトリラーゼおよびその用途 | |
US7033808B2 (en) | Carbonyl reductase, gene thereof and method of using the same | |
WO2005123921A1 (ja) | 新規グリセロール脱水素酵素、その遺伝子、及びその利用法 | |
AU773130B2 (en) | Method for isolating and selecting genes coding for enzymes, and suitable culture medium | |
EP2128258A1 (en) | Novel amidase, gene for the same, vector, transformant, and method for production of optically active carboxylic acid amide and optically active carboxylic acid by using any one of those items | |
JP2005102511A (ja) | 新規アルコール脱水素酵素、その遺伝子 | |
JP2008118985A (ja) | 溶菌酵素阻害剤、溶菌抑制剤及びポリ−ガンマ−グルタミン酸の分解抑制剤及びポリ−ガンマ−グルタミン酸の製造方法 | |
JP3330670B2 (ja) | アルケンモノオキシゲナーゼ、これをコードする遺伝子及び形質転換微生物並びにアルケンのエポキシ化方法 | |
JP3358686B2 (ja) | 新規なグルタミン酸デヒドロゲナーゼをコードする遺伝子及び該遺伝子を用いたグルタミン酸デヒドロゲナーゼの製造法 | |
WO2004020638A1 (ja) | グルコース脱水素酵素の製造方法 | |
JPH08504596A (ja) | アミダーゼ活性を有するポリペプチド、それらを製造するための遺伝学的ツール及び宿主微生物、並びに該ポリペプチドを用いる加水分解工程 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006539226 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005785206 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005785206 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005785206 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11576560 Country of ref document: US |